logo
Plus   Neg
Share
Email

Stock Alert: Immunomedics Down 11%

Shares of Immunomedics Inc. (IMMU) are declining 11% in Friday's morning trade.

Immunomedics' shares are currently trading at $9.48, down $1.17 or 10.99%, on the Nasdaq, on a higher-than average volume of 3.7 million shares.

There have been rumors in the air of a delay in upgrading a facility at Samsung Biologics, which was to produce commercial-scale quantities of the humanized antibody used in antibody-drug conjugate sacituzumab govitecan (IMMU-132).

Immunomedics is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer.

Meanwhile, reports also suggest that the delay is due to Immunomedics not receiving approval from FDA for its sacituzumab govitecan.

Sacituzumab govitecan is the company's lead drug candidate. The drug is in development for metastatic triple-negative breast cancer (mTNBC) advanced urothelial cancer (UC) and metastatic non-small cell lung cancer.

In January of this year, the FDA refused to approve Sacituzumab govitecan proposed for the treatment of patients with metastatic triple-negative breast cancer (mTNBC) who previously received at least two prior treatments due to issues related to Chemistry, Manufacturing and Control matters. The company has resubmitted the application, which is currently under FDA review with an action date of June 2.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Ford plans to bring back the Bronco as a dedicated off-road brand when it launches an all-new 4x4 SUV lineup on July 13. The automaker said it will introduce an all-new Bronco brand under the tagline, "Built Wild". The new lineup includes two-door and four-door models of the Bronco as well as the Bronco Sport compact SUV. J. M. Smucker Co. is recalling certain Natural Balance canned cat food, citing health concerns likely associated with increased levels of choline chloride, an animal growth promotant, the U.S. Food and Drug Administration said in a statement. The recall was initiated after receiving reports of adverse reactions. Polaris Industries Inc. is recalling certain Ranger and General Utility, as well as All-Terrain vehicles citing risks of crash, the U.S. Consumer Product Safety Commission said in a statement. The Medina, Minnesota-based company has called back about 26,730 units of Model Year 2019 - 2020 Ranger XP 1000 & Model Year 2020 General XP 1000 Utility vehicles.
Follow RTT